Cure8 research brief
The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted therapies.
Adults with Crohn’s disease; gastroenterologists and IBD clinicians; researchers focused on the microbiome, AIEC, and microbiome-based therapies.
The study enrolled 30 adults with Crohn’s disease and used a single colonoscopic FMT from one of two donors. The primary outcome was safety (adverse events over 12 weeks); no FMT-related serious adverse events were reported. Among 8 patients who were mucosally AIEC-positive at baseline and evaluable, all showed mucosal AIEC decolonization after FMT.
The authors performed shotgun metagenomics on fecal samples and 16S sequencing on ileal mucosal samples and found increased mucosal alpha diversity after FMT and donor-like shifts in microbial pathway profiles. Reduced fecal calprotectin correlated with increased mucosal diversity.
The study is an open-label pilot (ClinicalTrials.gov NCT05611866) and demonstrates feasibility and biological effects at the mucosal disease site, but it is small and not randomized.
Open‑label pilot with 30 participants and only 8 evaluable baseline mucosal AIEC‑positive patients; results are preliminary and hypothesis‑generating. Summary is grounded in the article abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
